膀胱腫瘍の一括切除における TFL 対 MOSES ホルミウム レーザー
膀胱腫瘍の一括切除におけるツリウムファイバーレーザー(TFL)とMOSESホルミウムレーザーの比較:ランダム化対照臨床研究
The goal of this randomized clinical trial is to determine if there is difference in pathological and clinical outcomes between MOSES and TFL in the transurethral laser enucleation of bladder tumors.
The main question it aims to answer is:
Is there a difference in pathological and clinical outcomes between MOSES Holmium and Thulium Fiber Laser (TFL) in the transurethral laser enucleation of bladder tumors?
Participants will randomized to either TFL of MOSES arm for their bladder resection procedure.
調査の概要
詳細な説明
An estimated 12,500 Canadians are diagnosed with bladder cancer each year. Diagnosis and treatment involve transurethral (through the urethra) resection of tumor or tissue called the TURBT procedure. This procedure yields excellent results and minimal morbidity and mortality but has a high recurrence rate, difficulties in the pathologic interpretation of the specimen (due to cautery effect), and procedure-related complications (excessive bleeding, bladder perforation, bowel injury, and inadvertent extensive injury to urethra) that may delay treatments such as chemotherapy which would further impact oncologic outcomes. With the advancement of technology, new methods of transurethral tumor removal have emerged, such as the use of laser energy. Using laser energy, the tumour is resected in one piece, whereas the TURBT approach requires breaking the tumor into pieces. This allows for better pathology analysis that can determine treatment pathways for the patient, as well as reduces the risk of complications. The standard lasers used have been the MOSES Holmium laser and the Thulium Fiber Laser (TFL).
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Ontario
-
Thunder Bay、Ontario、カナダ、P7B 6V4
- Thunder Bay Regional Health Sciences Centre
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Over 18 years of age at the time of enrollment.
- Patients presented with visual criteria suggesting bladder tumor by outpatient cystoscopy will be legible for inclusion.
Exclusion Criteria:
- Tumors deemed not eligible for laser resection as determined by the Urologist e.g. obvious muscle-invasive or metastatic at presentation
- Synchronous either urethral tumors or upper urinary tract tumor
- History of Carcinoma in situ
- Contracted bladder
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Thulium Fibre Laser
Participants randomized to this arm will undergo bladder resection using the TFL laser |
Participant undergoing bladder tumour resection that has been randomized to this arm. |
|
アクティブコンパレータ:MOSES Holmonium
Participants randomized to this arm will undergo bladder resection using the MOSES holmium laser. |
Participant undergoing bladder tumour resection that has been randomized to this arm. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Presence of muscularis propria
時間枠:1 day post-procesure
|
Presence of muscularis propria (bladder muscle cells) in the pathology sample of the bladder tumour |
1 day post-procesure
|
|
Incidence of inconclusive pathology
時間枠:1 day post-procedure
|
Incidence of inconclusive pathology due to specimen artifact |
1 day post-procedure
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Tumor-free rate (TFR)
時間枠:6 to 12 weeks post-procedure
|
As per the follow-up cystoscopy, TFR is defined as the absence of any residual tumor detectable by cystoscopy. |
6 to 12 weeks post-procedure
|
|
Total operative time
時間枠:Intraoperative
|
In minutes measured from anesthesia induction until placement of the urethral catheter |
Intraoperative
|
|
Total procedural time
時間枠:Intraoperative
|
In minutes, measured from the time the cystoscope sheath is inserted into the participant to the time the cystoscope has been removed |
Intraoperative
|
|
Number of recurrences
時間枠:12 weeks post-procedure
|
Defined as any tumor detection by follow-up cystoscopy after the initial resection |
12 weeks post-procedure
|
|
Total blood loss
時間枠:6 hours post-procedure
|
Defined as a drop in hemoglobin level from pre-op |
6 hours post-procedure
|
|
Rate of complications
時間枠:4 weeks post-procedure
|
Percentage of participants with post-operative complications |
4 weeks post-procedure
|
|
Number of inconclusive pathology
時間枠:1 day post-procedure
|
Number of inconclusive pathology due to thermal effect artifact. |
1 day post-procedure
|
|
Lasing time
時間枠:Intraoperative
|
In minutes, defined as the time the laser was in use, not including pedal pauses |
Intraoperative
|
|
Total energy used
時間枠:Intraoperative
|
Measured in kilojoules |
Intraoperative
|
|
Frequency and severity of peri-operative complications
時間枠:Intraoperative
|
Reported according to Clavien-Dindo |
Intraoperative
|
協力者と研究者
捜査官
- 主任研究者:Ahmed Z Ahmed、Thunder Bay Regional Health Sciences Centre
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- RP-1007
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。